Acutus Medical Archives - Page 2 of 3 - Medical Design Sourcing

The biggest medtech personnel moves so far in 2022

In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit.

At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. Throughout just over half of 2022, we’ve already seen a slew of major moves around some of the space’s most powerful players.

Here is a list of some of the biggest personnel changes in medtech so far in 2022:

3M’s healthcare president retires 3M Health Care Business Group President Mojdeh Poul [Image courtesy of 3M]Mojdeh Poul, the president of 3M’s healthcare business, announced in May that she would retire from the position and her retirement was made effective on July 1.

Poul joined 3M in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions, including infection prevention, 3M Canada, and sa…

Acutus Medical names new CEO, reports preliminary Q2 revenues

[Image from Acutus]Acutus Medical (Nasdaq:AFIB) announced today that it appointed David Roman as its new president and CEO.

Roman’s appointment to the positions, as well as to a membership spot on the company’s board of directors, was made effective immediately.

“Acutus benefits from a dedicated and passionate team, and as CEO I am excited to continue driving the adoption of our electrophysiology mapping and therapy solutions as well as improving our operational and financial performance,” Roman said in a news release. “We have a tremendous amount of opportunity ahead of us, and I am confident in our ability to execute on our plans and maintain positive momentum in 2022 and beyond.”

Roman joined Acutus as CFO in March 2021. He has been serving as interim CEO since May 13, 2022, and will continue as CFO until a replacement is appointed.

He oversaw the sale of the company’s left-heart access portfolio t…

Design challenges to overcome when developing cardiac ablation devices

Acutus Medical’s AcQBlate Force sensing ablation catheter. Image courtesy of Acutus Medical

It’s about figuring out how and where to go with the cardiac ablation and then engineering the best catheter-based delivery device, according to a top Acutus Medical scientist.

Cardiac ablation is when a physician intentionally destroys a small amount of tissue in the heart to treat and prevent heart rhythm problems. The procedure creates therapeutic scars in the heart to block the irregular electrical signals that cause an uneven heartbeat.

To perform cardiac ablation, a physician inserts a thin, flexible catheter through veins or arteries into the heart. Sensors on the tip of the catheter detect the electrical signals inside the heart, which allows a cardiologist to pinpoint which area of the heart requires ablation.

Ablation devices mostly use heat (radiofrequency energy), extreme cold (cryoablation)…

Acutus completes first closing in left-heart access portfolio sale to Medtronic

Acutus Medical (Nasdaq:AFIB) announced today that it completed the first of two closings in its portfolio sale to Medtronic (NYSE:MDT).

Carlsbad, California-based Acutus announced in April that it entered into a definitive agreement to sell its left-heart access portfolio to Medtronic for $50 million. The company’s left-heart access portfolio includes its AcQCross line of sheath-compatible septal crossing devices, AcQGuide Mini integrated crossing device and sheath, AcQGuide Flex steerable introducer with transseptal dilator and needle and the AcQGuide Vue steerable sheath.

According to a news release, Acutus completed the first closing of the sale yesterday, with Medtronic paying the cash consideration of $50 million at the closing. Acutus will be eligible to receive contingent consideration payments of up to $37 million associated with certain manufacturing and regulatory milestones.

In addition to those payments, Acutus is eligible to receive up…

What is pulsed-field ablation? Here’s what you need to know

Top experts at Boston Scientific, Medtronic and Acutus Medical shared insights about pulsed-field ablation’s potential at DeviceTalks Boston. Part of the Farapulse pulsed-field ablation system, the Farawave single-shot catheter is designed to create durable and circumferential lesions. [Image courtesy of Boston Scientific]Pulsed-field ablation is a non-thermal method for cardiac ablation that has the potential to positively disrupt the way atrial fibrillation is treated.

PFA’s roots go back to the dc ablation tech of the 1980s. These days, PFA generally involves high-voltage electric pulses from a catheter-delivered electrode or electrodes, delivered each at a tiny fraction of a second. Its potential advantages versus radiofrequency ablation or cryoablation include the characteristic that heart muscle tissue can be especially susceptible to it, while other types of surrounding tissue are injury resistant.

It’s hard these days to find a cardiac device company…

What is pulsed-field ablation? Here’s what you need to know

Top experts at Boston Scientific, Medtronic and Acutus Medical shared insights about pulsed-field ablation’s potential at DeviceTalks Boston.

Part of the Farapulse pulsed-field ablation system, the Farawave single-shot catheter is designed to create durable and circumferential lesions. [Image courtesy of Boston Scientific]

Pulsed-field ablation is a non-thermal method for cardiac ablation that has the potential to positively disrupt the way atrial fibrillation is treated.

PFA’s roots go back to the dc ablation tech of the 1980s. These days, PFA generally involves high-voltage electric pulses from a catheter-delivered electrode or electrodes, delivered each at a tiny fraction of a second. Its potential advantages versus radiofrequency ablation or cryoablation include the characteristic that heart muscle tissue can be especially susceptible to it, while other types of surrounding tissue are injury resistant.

…

Acutus Medical sells left-heart access portfolio to Medtronic in $50M deal

Acutus Medical (NSDQ:AFIB) today announced that it has entered a definitive agreement to sell its left-heart access portfolio to Medtronic (NYSE:MDT) for $50 million.

Medtronic will make an upfront cash payment to Princeton, N.J.-based Acutus Medical of $50 million upon the initial closing of the transaction, which is subject to the satisfaction of customary closing conditions including expiration or early termination of all applicable waiting periods under antitrust laws. The deal is also subject to Acutus’ debt refinancing and contingent consideration payments over time based on the achievement of certain milestones and future sales, according to the company.

Acutus Medical’s left-heart access portfolio includes its AcQCross line of sheath-compatible septal crossing devices, AcQGuide Mini integrated crossing device and sheath, AcQGuide Flex steerable introducer with transseptal dilator and needle and the AcQGuide Vue steerable sheath.

In co…

What is the future of cardiac ablation?

Boston Scientific in July 2021 exercised its option to acquire the remaining shares of PFA tech developer Farapulse. [Image courtesy of Boston Scientific]Pulsed-field ablation (PFA) — a non-thermal method for cardiac ablation — has the potential to positively disrupt the atrial fibrillation market.

Amid the excitement around the technology, Medtronic announced in January that it would acquire cardiac mapping and ablation technology developer Affera for nearly $1 billion. Meanwhile, Boston Scientific in February closed its $1.75 billion acquisition of Baylis Medical — the creator of advanced transseptal puncture platforms to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart. Months before, Boston Scientific exercised its option to acquire the remaining shares of PFA tech developer Farapulse.

Come to DeviceTalks Boston — May 10-11, 2022 — and hear from leaders at Boston Scientific, Medtronic an…

What is the future of cardiac ablation?

Boston Scientific in July 2021 exercised its option to acquire the remaining shares of PFA tech developer Farapulse. [Image courtesy of Boston Scientific]

Pulsed-field ablation (PFA) — a non-thermal method for cardiac ablation — has the potential to positively disrupt the atrial fibrillation market.

Amid the excitement around the technology, Medtronic announced in January that it would acquire cardiac mapping and ablation technology developer Affera for nearly $1 billion. Meanwhile, Boston Scientific in February closed its $1.75 billion acquisition of Baylis Medical — the creator of advanced transseptal puncture platforms to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart. Months before, Boston Scientific exercised its option to acquire the remaining shares of PFA tech developer Farapulse.

Come to DeviceTalks Boston — May 10-11, 2…

Acutus Medical announces ‘ reduction in force’ amid restructuring

Acutus Medical (NSDQ:AFIB) announced today that it has undertaken a corporate restructuring that includes cutting some of its staff.

Part of the restructuring includes a planned reduction in force (RIF) for the developer of technologies for diagnosing and treating cardiac arrhythmias. A spokesperson for the company confirmed that Acutus is not disclosing the number of notified employees, but the company noted that the action is subject to the WARN Act, meaning it involves more than 50 people.

“We have undertaken a detailed review of our strategic priorities, the external environment, and cost structure and are restructuring the Company to sharpen our focus and strengthen our financial position,” Acutus President & CEO Vince Burgess said in a news release. “While challenging, this restructuring is a critical step in positioning Acutus for the future, and we are committed to treating impacted employees with respect and support through this period of change.”<…

AliveCor, Acutus partner on remote monitoring pilot study

AliveCor and Acutus Medical (NSDQ:AFIB) today announced a collaboration to study the integration of data collection tools in cardiology.

The companies plan to launch a post-market U.S. pilot study in the third quarter of 2021 to gain insights on how physicians can use AliveCor’s KardiaMobile electrocardiogram (ECG) device to facilitate pre-ablation and/or post-ablation remote monitoring to aid in the decision making while managing cardiac arrhythmia patients, according to a news release.

Information gathered through the collaboration is intended to enable more informed decisions in treating complex arrhythmias to potentially improve patient outcomes and advance the field of arrhythmia treatment and disease management, the companies said.

“Utilizing data from across the continuum of care to complement our core mapping and therapy technologies furthers our vision to become the provider-of-choice and democratize the treatment of complex arrhythm…

FDA clears Acutus Medical suite of universal transseptal crossing devices

Acutus Medical announced that it received FDA clearance for its AcQCross family of universal transseptal crossing devices.

Carlsbad, Calif.-based Acutus touts the AcQCross system as the first and only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ suite of sheaths, as well as with sheaths sold by other manufacturers, according to a news release.

Get the full story at our sister site, Medical Tubing & Extrusion.